TY - JOUR
T1 - Loss of Visual Field Among Patients with Birdshot Chorioretinopathy
AU - Thorne, Jennifer E.
AU - Jabs, Douglas A.
AU - Kedhar, Sanjay R.
AU - Peters, George B.
AU - Dunn, James P.
N1 - Funding Information:
This study was supported by Grants EY-13707 (Dr Thorne) and EY-00405 (Dr Jabs) from the National Eye Institute, Bethesda, Maryland. Dr Thorne is the recipient of a Research to Prevent Blindness Harrington Special Scholars award. The authors indicate no financial conflict of interest. Involved in design and conduct of study (J.E.T., D.A.J., G.B.P.); collection and management of the data (J.E.T.); provision of patients and resources (J.E.T., D.A.J., S.R.K., J.P.D.); analysis and interpretation of the data (J.E.T., D.A.J.); preparation of manuscript (J.E.T.); and review and approval of the manuscript (J.E.T., D.A.J., G.B.P., S.R.K., J.P.D.). This study was approved by the Johns Hopkins University School of Medicine’s Institutional Review Board in accordance with the Declaration of Helsinki. This study is in compliance with HIPAA regulations.
PY - 2008/1
Y1 - 2008/1
N2 - Purpose: To describe the prevalence and incidence of loss of visual field among patients with birdshot chorioretinopathy (BSCR) and to describe the effect of therapy on such field loss in these patients. Design: Retrospective cohort study. Method: setting: Single-center, academic practice. study population: Fifty-five patients with BSCR evaluated from January 1984 through July 2006. procedures: Demographic, clinical, and visual field data were collected retrospectively. outcome measures: Visual field loss is defined as an abnormal visual field score on Goldmann perimetry within six months of presentation and during follow-up; rate of visual field loss is defined as the number of degrees lost per year. Results: Forty-eight eyes of 24 patients had Goldmann visual fields performed within six months of presentation and of these eyes, 75% and 56% had abnormal field scores for the I-4 and IV-4 isopters, respectively. Of the 28 eyes of 14 patients that received immunosuppressive drug therapy during the follow-up period, the rate of visual field "loss" prior to treatment was 107 degrees/year (95% confidence interval [CI]: 65, 148 degrees/year) and 56 degrees/year (95% CI: 5, 109 degrees/year) for the I-4 and IV-4 isopters, respectively. The rate of "gain" after institution of immunosuppressive drug therapy was 53 degrees/year (95% CI: 10 degrees lost/year, 98 degrees gained/year) and 30 degrees/year (95% CI: 20 degrees lost/year, 81 degrees gained/year) for each isopter. Conclusions: Visual field loss was common among our patients with BSCR. Usage of immunosuppressive drug therapy may reverse some of the visual field loss while therapy is employed.
AB - Purpose: To describe the prevalence and incidence of loss of visual field among patients with birdshot chorioretinopathy (BSCR) and to describe the effect of therapy on such field loss in these patients. Design: Retrospective cohort study. Method: setting: Single-center, academic practice. study population: Fifty-five patients with BSCR evaluated from January 1984 through July 2006. procedures: Demographic, clinical, and visual field data were collected retrospectively. outcome measures: Visual field loss is defined as an abnormal visual field score on Goldmann perimetry within six months of presentation and during follow-up; rate of visual field loss is defined as the number of degrees lost per year. Results: Forty-eight eyes of 24 patients had Goldmann visual fields performed within six months of presentation and of these eyes, 75% and 56% had abnormal field scores for the I-4 and IV-4 isopters, respectively. Of the 28 eyes of 14 patients that received immunosuppressive drug therapy during the follow-up period, the rate of visual field "loss" prior to treatment was 107 degrees/year (95% confidence interval [CI]: 65, 148 degrees/year) and 56 degrees/year (95% CI: 5, 109 degrees/year) for the I-4 and IV-4 isopters, respectively. The rate of "gain" after institution of immunosuppressive drug therapy was 53 degrees/year (95% CI: 10 degrees lost/year, 98 degrees gained/year) and 30 degrees/year (95% CI: 20 degrees lost/year, 81 degrees gained/year) for each isopter. Conclusions: Visual field loss was common among our patients with BSCR. Usage of immunosuppressive drug therapy may reverse some of the visual field loss while therapy is employed.
UR - http://www.scopus.com/inward/record.url?scp=37249069437&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.08.039
DO - 10.1016/j.ajo.2007.08.039
M3 - Article
C2 - 17997394
AN - SCOPUS:37249069437
SN - 0002-9394
VL - 145
SP - 23-28.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 1
ER -